Background: Treatment response biomarkers that rapidly identify and prioritize effective interventions are urgently needed to improve treatment for people with tuberculosis (TB). However, trial efficacy is limited by culture-based outcome monitoring, which is unreliable and technically demanding. Recent publication of the World Health Organisation (WHO) Target Product Profiles (TPPs) offers an interpretable consensus benchmark for which to evaluate novel biomarkers for treatment response. Objectives: We sought to conduct an update to our previous review to evaluate all newly published TB treatment biomarkers and evaluate their performance against WHO TPP standards. Methods: The protocol was registered with PROSPERO (CRD 42021225507). We searched PubMed, Embase and Cochrane databases for studies including participants ≥15 years old with confirmed pulmonary TB with culture as a reference, regardless of current or previous TB treatment and resistance profile. We excluded all studies not reported in English, Portuguese, German or French, studies in patients with extrapulmonary TB, and conference abstracts and proceedings. We performed a risk of bias assessment using the QUADAS-2 tool. We extracted performance data including sensitivity, specificity, area under the receiver-operator curve (AUC), and correlation measures (Rho). We grouped biomarkers to align with the culture-based endpoints used in phase 2 and 3 TB clinical trials: α, bacterial load estimates; β, interim study endpoints; γ, on-treatment markers for long-term outcome; and δ, baseline risk stratification markers for long-term outcome prediction. We then compared them to the WHO TPP thresholds for a baseline or on-treatment marker for long-term outcome. Results: From 30 studies involving 4391 patients, we extracted 656 novel biomarker entries. From these, we extracted complete data from 385 that were reported with at least one relevant performance metric. We categorised each into α (n=45), β (n=90), γ (n= 165) or δ (n=85) groups, and found 21 entries that reached the minimum WHO TPP thresholds, including one for TB disease recurrence. Despite these encouraging results, the biomarker research field would be better equipped with access to guidance on conduct of biomarker research, including data analysis and reporting.